Additionally, studies had to report at least one of the following outcomes: incidence of MACE (e.g., myocardial infarction, stroke, or cardiovascular death), levels of inflammatory biomarkers (hs-CRP or IL-6), or adverse events associated with the intervention. The gene discussed is IL6; the disease is stroke disorder.